Availability of EpiPen® 300mcg Adrenaline (epinephrine) Auto-Injector - 22 Jan 2018

IMPORTANT NOTIFICATION: Availability of EpiPen® 300mcg Adrenaline (epinephrine) Auto-Injector

EpiPen shortage 22 Jan 2018

EpiPen® 300mcg shortage

  • Mylan has announced a shortage of EpiPen 300mcg adrenaline (epinephrine) autoinjectors.

  • Supply of EpiPen Jr 150mcg adrenaline (epinephrine) autoinjectors is not affected.

  • Stock of EpiPen 300mcg is expected to be available in pharmacies from mid-February 2018. 

  • A process has been put in place by Mylan to ensure those at risk of anaphylaxis have access to the treatment they may need. Mylan has requested that patients requiring an EpiPen 300mcg autoinjector contact their local pharmacy. Pharmacies can then contact Mylan by phoning 1800 274 276 or by emailing This email address is being protected from spambots. You need JavaScript enabled to view it.  to obtain instructions on how to access emergency supply. 

  • Individuals will be able to access one in-date adrenaline autoinjector until the shortage resolves in mid-February 2018.

  • Individuals and/or carers who require support should contact the national patient support organisation, Allergy & Anaphylaxis Australia via contact us or call 1300 728 000 

  • In the case of anaphylaxis individuals and/or carers should follow instructions on their ASCIA Action Plan (i.e. Give EpiPen and call an ambulance).

Use of expired adrenaline (epinephrine) autoinjectors

  • It is important to note that a device expiring in February 2018 does not actually expire until the end of that month, not the start of that month.

  • Whilst the use of an expired adrenaline (epinephrine) autoinjector is not ideal, research suggests that recently expired devices are effective in an emergency.

  • The shortage is due to a manufacture delay at Meridian Medical Technologies in the USA, a Pfizer company.

  • Mylan Australia have assured A&AA and ASCIA they are monitoring the situation closely and working diligently with Meridian to stabilise the supply of EpiPen as quickly as possible.

  • A&AA will continue to monitor the situation closely and advocate on behalf of consumers at risk of anaphylaxis.

Regards,

Maria Said, CEO, Allergy & Anaphylaxis Australia

pdfAvailability of EpiPen® 300mcg Adrenaline (epinephrine) Auto-Injector - 22 Jan 2018625.37 KB

Acute Anaphylaxis CSS
Acute Anaphylaxis Clinical Care Standard - Learn more...
Atopic Dermatitis
allergy250K teens/young adults
Food allergy training

Our Supporters

Diamond


Viatris
Sanofi
Nestle
Allergy Concepts

Platinum


  • Bulla
  • NSW Food Authority
  • Novartis
  • Pfizer

Gold


  • dbv technologies
  • Mondelez
  • Nurticia
Silver

  • abbvie
  • Australian Camps Association
  • Bayer
  • Sanctuary Early Learning
  • Sweet William


© 2023 ALLERGY & ANAPHYLAXIS AUSTRALIA
ABN: 70 693 242 620

 



ALLERGY & ANAPHYLAXIS AUSTRALIA
is supported by funding from the
Australian Government,
Department of Health.


ALLERGY & ANAPHYLAXIS AUSTRALIA acknowledges and pays respect to the traditional custodians of the lands on which we work, live and play.

IN AN EMERGENCY

If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.